• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cullinan Therapeutics Inc.

    2/27/25 7:11:50 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEM alert in real time by email
    S-8 1 cgem-20250227.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-_____

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    CULLINAN THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    81-3879991

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    One Main Street

    Suite 1350

    Cambridge, MA

    02142

    (Address of principal executive offices)

    (Zip Code)

    Cullinan Therapeutics, Inc. 2021 Stock Option and Incentive Plan
    Cullinan Therapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Nadim Ahmed

    President and Chief Executive Officer

    Cullinan Therapeutics, Inc.

    One Main Street

    Suite 1350

    Cambridge, MA 02142
    (Name and Address of Agent For Service)

    (617) 410-4650

    (Telephone Number, Including Area Code, of Agent For Service)

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

     

    Accelerated filer

     

    ☐

     

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

     

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Statement of Incorporation by Reference

    This Registration Statement on Form S-8, relating to the 2021 Stock Option and Incentive Plan (the “2021 Stock Plan”) of Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (the “Registrant”) and the 2021 Employee Stock Purchase Plan of the Registrant (the “ESPP”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-251943, filed with the Securities and Exchange Commission (the “SEC”) on January 7, 2021 by the Registrant, relating to the 2021 Stock Plan and the ESPP, (ii) the Registration Statement on Form S-8, File No. 333-263428, filed with the SEC on March 10, 2022 by the Registrant, relating to the 2021 Stock Plan and the ESPP, (iii) the Registration Statement on Form S-8, File No. 333-270387, filed with the SEC on March 9, 2023 by the Registrant relating to the 2021 Stock Plan and the ESPP, and (iv) the Registration Statement on Form S-8, File No. 333-277914, filed with the SEC on March 14, 2024 by the Registrant relating to the 2021 Stock Plan and the ESPP, except for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

    Exhibit

    Number

    Description

    4.1

     

    Second Amended and Restated Certificate of Incorporation of the Registrant, as amended by the Certificate of Amendment, effective as of April 15, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).

     

     

     

    4.2

     

    Third Amended and Restated Bylaws of the Registrant, effective as of April 15, 2024 (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K filed with the SEC on April 16, 2024).

     

     

     

    5.1*

     

    Opinion of Ropes & Gray LLP, counsel to the Registrant.

     

     

     

    23.1*

     

    Consent of Ropes & Gray LLP (included in Exhibit 5.1).

     

     

     

    23.2*

     

    Consent of KPMG LLP, Independent Registered Public Accounting Firm.

     

     

     

    24.1*

     

    Power of Attorney (included on the signature pages of this registration statement).

     

     

     

    99.1

     

    2021 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-251512) filed with the SEC on January 4, 2021).

     

     

     

    99.2

     

    2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-251512) filed with the SEC on January 4, 2021).

     

     

     

    107*

     

    Filing Fee Table.

     

     

    *

    Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 27th day of February, 2025.

    Cullinan Therapeutics, Inc.

    Date: February 27, 2025

    By:

    /s/ Nadim Ahmed

    Name: Nadim Ahmed

    Title: President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Cullinan Therapeutics, Inc., hereby severally constitute and appoint Nadim Ahmed and Mary Kay Fenton, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cullinan Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Name

    Title

    Date

     

     

     

     

     

    /s/ Nadim Ahmed

    President, Chief Executive Officer and Director

    February 27, 2025

    Nadim Ahmed

    (Principal Executive Officer)

     

     

     

     

     

    /s/ Mary Kay Fenton

     Chief Financial Officer

    February 27, 2025

    Mary Kay Fenton

    (Principal Financial and Accounting Officer)

     

     

     

     

     

    /s/ Anne-Marie Martin

    February 27, 2025

    Anne-Marie Martin

    Director

     

     

     

     

     

    /s/ David Meek

     

     

     

    February 27, 2025

    David Meek

     

    Director

     

     

     

     

     

     

     

    /s/ Anthony Rosenberg

    February 27, 2025

    Anthony Rosenberg

    Director

    /s/ David P. Ryan, M.D.

     

     

    February 27, 2025

    David P. Ryan, M.D.

     

    Director

     

     

     

     

     

     

     

    /s/ Mary Thistle

     

     

     

    February 27, 2025

    Mary Thistle

     

    Director

     

     

     

     

     

     

     

    /s/ Stephen Webster

    February 27, 2025

    Stephen Webster

     Director

     

     


    Get the next $CGEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGEM

    DatePrice TargetRatingAnalyst
    10/24/2024$30.00Buy
    UBS
    5/1/2024$40.00Buy
    Stifel
    4/15/2024Outperform
    William Blair
    2/15/2024$30.00Outperform
    Wedbush
    6/15/2023Outperform
    TD Cowen
    11/21/2022$20.00Buy
    BTIG Research
    More analyst ratings

    $CGEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/14/24 5:05:22 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/14/24 4:24:39 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/12/24 2:23:54 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cullinan Therapeutics Inc.

      10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      5/8/25 7:24:46 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      5/8/25 7:21:22 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Cullinan Therapeutics Inc.

      DEFA14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      4/25/25 6:58:58 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Financials

    Live finance-specific insights

    See more
    • Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first

      5/8/25 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028 CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted t

      2/27/25 7:00:32 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected mid-year 2025 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 202

      11/7/24 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Cullinan Therapeutics with a new price target

      UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

      10/24/24 6:18:20 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Cullinan Management with a new price target

      Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00

      5/1/24 6:23:49 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Cullinan Management

      William Blair initiated coverage of Cullinan Management with a rating of Outperform

      4/15/24 7:38:02 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

      CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast

      4/29/24 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

      CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012.   Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his

      11/2/22 8:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

      CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a

      8/15/22 4:57:42 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first

      5/8/25 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

      CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren's disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjögren's disease (SjD) in the U.S. The Company previously received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) Applicatio

      4/29/25 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (ex20ins) who have received prior therapy will be presented in an oral abstract session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 30–June 3, 2025. The data will include results from the Phase 2b portion of the study, which explored zipalertinib monotherapy in patients with advanced or metastati

      4/23/25 10:14:04 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Ahmed Nadim sold $106,872 worth of shares (12,529 units at $8.53), decreasing direct ownership by 3% to 430,621 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:07 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Jones Jeffrey Alan sold $41,754 worth of shares (4,895 units at $8.53), decreasing direct ownership by 3% to 174,164 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:09 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Michaelson Jennifer sold $32,039 worth of shares (3,756 units at $8.53), decreasing direct ownership by 3% to 142,004 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:06 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care